Blaze secures FDA fast track designation for its BLZ-100 clinical trial
US-based biotechnology firm Blaze Bioscience has secured the US Food and Drug Administration (FDA) fast track designation for its clinical programme evaluating tozuleristide (BLZ-100) for pediatric brain tumours.